Homoharringtonine (Omacetaxine mepesuccinate and HHT; trade name Synribo) is a naturally occurring and cytotoxic pharmaceutical substance that is indicated for treatment of chronic myeloid leukemia (CML). It acts by inhibiting translation elongation. It is a natural product first discovered in Cephalotaxus harringtonia, now manufactured by hemi-synthesis. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).

纯度：≥98%

CAS：26833-87-4